14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Wed, 8 May 2024

Trading levels for ABEO

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 5.25 9.90 %
R2 5.05 5.67 %
R1 4.93 3.05 %
Current price: 4.78
Support S1 4.52 -5.42 %
S2 4.40 -8.04 %
S3 4.19 -12.27 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 0 .
R2 5.28 10.46 %
R1 4.90 2.51 %
Current price 4.78
Support S1 4.60 -3.77%
S2 4.14 -13.39%
S3 3.91 -18.20%

ABEO Predictions History

3 years ago
odaysalem18.218707 predicted that ABEO for 2021-03-01 is going

Rank:

3 years ago
JS predicted that ABEO for 2021-02-08 is going $2.52 (-25.66%)

3 years ago
s.petrov predicted that ABEO for 2021-02-08 is going $3.00 (-11.50%)

Rank:

3 years ago
JS predicted that ABEO for 2020-12-02 is going $1.46 (-6.41%)

3 years ago
JS predicted that ABEO for 2020-10-02 is going $1.11 (5.71%)

3 years ago
iHustle84 predicted that ABEO for 2020-10-02 is going $0.780 (-25.71%)

3 years ago
DeMichael Franklin predicted that ABEO for 2020-10-02 is going $0.400 (-61.90%)

Rank:

3 years ago
JS predicted that ABEO for 2020-10-01 is going $0.91 (-12.95%)

3 years ago
iHustle84 predicted that ABEO for 2020-10-01 is going $0.89 (-15.24%)

3 years ago
DeMichael Franklin predicted that ABEO for 2020-10-01 is going $0.400 (-60.78%)

Rank:
Click to get the best stock tips daily for free!

About Abeona Therapeutics Inc.

Abeona Therapeutics. Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease;... ABEO Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT